ImmunoGen Announces Webcast of Presentation at Upcoming SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

ImmunoGen Inc. (Nasdaq: IMGN) announced participation in the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 3:40 PM ET. Chief Financial Officer Susan Altschuller and Chief Medical Officer Anna Berkenblit will engage in a fireside chat. A live webcast will be accessible via the company’s website, with a replay available afterward. ImmunoGen specializes in developing next-generation antibody-drug conjugates aimed at improving cancer treatment outcomes by offering enhanced anti-tumor activity and better tolerability.

Positive

• Participation in a recognized industry conference can enhance visibility and investor interest.
• Focus on next-generation antibody-drug conjugates positions ImmunoGen to potentially capture a larger market share in cancer treatments.

Negative

• None.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming SVB Leerink 10th Annual Global Healthcare Conference. The presentation is scheduled for February 25, 2021 at 3:40pm ET.

A webcast of the presentation will be accessible through the Investors and Media section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005761/en/

FAQ

When will ImmunoGen participate in the SVB Leerink 10th Annual Global Healthcare Conference?

ImmunoGen will participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 3:40 PM ET.

Who from ImmunoGen will speak at the SVB Leerink conference?

Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will speak at the conference.

Where can I watch the ImmunoGen conference presentation?

The presentation will be available via a live webcast on ImmunoGen's website, with a replay accessible afterward.

What is ImmunoGen's focus in cancer treatment?

ImmunoGen develops next-generation antibody-drug conjugates aimed at improving outcomes for cancer patients.